NVS Stock Summary and Trading Ideas (Novartis Ag | NYSE:NVS)

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

Novartis Ag trades on the NYSE stock market under the symbol NVS.

As of October 21, 2026, NVS stock price climbed to $153.93 with 963,735 million shares trading.

NVS has a beta of 0.09, meaning it tends to be less sensitive to market movements. NVS has a correlation of 0.00 to the broad based SPY ETF.

NVS has a market cap of $292.58 billion. This is considered a Mega Cap stock.

Last quarter Novartis Ag reported $14 billion in Revenue and $2.41 earnings per share. This beat revenue expectation by $284 million and exceeded earnings estimates by $.25.

In the last 3 years, NVS traded as high as $170.46 and as low as $92.19.

The top ETF exchange traded funds that NVS belongs to (by Net Assets): DFIV, DFAI, DFIC, AVDE, DIHP.

NVS has outperformed the market in the last year with a price return of +20.4% while the SPY ETF gained +16.3%. However, in the short term, NVS had mixed performance relative to the market. It has underperformed in the last 3 months, returning +2.9% vs +4.4% return in SPY. But in the last 2 weeks, NVS shares have fared better than the market returning +9.3% compared to SPY -0.8%.

NVS support price is $151.55 and resistance is $155.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVS shares will trade within this expected range on the day.